Black Friday saleUp to 70% OFF

Multiple Time Frame Analysis

IFCI - Multiyear Breakout - MonthlyIFCI - Multiyear Breakout - Monthly Multi-Year Breakout: The chart indicates a multi-year breakout with strong volume, suggesting a potential long-term uptrend. 16yrs high Breakout: Neckline marking a 16yrs breakout, which could be a shorter-term confirmation of the trend. Support Level: The low of the breakout candle is marked as a support level at 59, which can be a critical point to watch for potential pullbacks. This setup looks promising for those interested in technical analysis and long-term investments. IFCI, previously known as Industrial Finance Corporation of India, is an Indian Government owned non banking finance company established to cater to the long-term finance needs of the industrial sector. IFCI Ltd. recently announced its Q1 results for the period ending June 30, 2024. Here are the key highlights: Revenue: The company reported a revenue of ₹4,051.2 million, up from ₹3,243.6 million in the same quarter last year. Net Loss: The net loss decreased to ₹1,082 million from ₹1,399.8 million year-over-year (YoY), marking a 24.64% improvement. Earnings Per Share (EPS): The EPS for Q1 stands at ₹-0.44, a decrease of 4.34% YoY2. Operating Income: Despite a 90.05% quarter-over-quarter (QoQ) decline, the operating income increased by 106.82% YoY. SG&A Expenses: Selling, General & Administrative expenses saw a reduction of 29.44% QoQ and 8.04% YoY. These results indicate that while IFCI has made significant annual progress, it faced challenges in the most recent quarter. The reduction in SG&A expenses suggests improved operational efficiency, but the decline in EPS highlights ongoing profitability challenges
Editors' picks
NSE:IFCILong
by VCharts_TA
3
Devyani International Potential Bullish MomentumFollowing a notable consolidation phase that commenced in January 2024, Devyani International has exhibited promising technical signals, suggesting a potential shift towards a bullish trend. Last week, the stock successfully breached the pivotal resistance level of 185 on the weekly timeframe, which is a critical psychological and technical milestone. The 20 EMA has crossed above the 50 EMA on the weekly chart, a classic indicator of bullish momentum known as a "Golden Cross." This crossover typically signals a potential uptrend and aligns with the stock's recent move above the 185 pivot point. Both the daily and weekly RSI readings have indicated bullish momentum, suggesting the stock has been gaining strength relative to its price action over the observed periods. The MACD indicator on both daily and weekly charts is also reflecting bullish dynamics, with the MACD line crossing above the signal line. The stock has managed to close above the equilibrium level, a point where buying and selling pressures are balanced, on both the daily and weekly charts. A sustained close above this level could signify strong sentiment among investors, further corroborating the potential for upward momentum. A Change of Character has been observed on the weekly chart, indicating a shift from prior selling exhaustion to potential buying interest. This technical pattern often precedes substantial price movements, and in this case, it may suggest that sellers are losing control, paving the way for bulls to take the lead. Given the aforementioned technical indicators and patterns, the next resistance level is identified at approximately 236. Should the stock continue its bullish trajectory, this represents a potential upside of around 25% in the short term. Traders should closely monitor volume trends and broader market sentiment to fortify their positions. Disclaimer: The information provided in this stock analysis is for informational and educational purposes only and should not be construed as financial advice. Always seek the advice of a qualified financial advisor or conduct your own research before making any investment decisions.
NSE:DEVYANILong
by NiftyNotions
JUBLPHARMA - 6 Years -Consolidation breakout - WklyJUBLPHARMA - Price consolidated 6 years and gave breakout with very good volume. Good setup to enter if it retest the breakout around 1000 levels. Name - JUBLPHARMA Pattern - Consolidation Breakout Timeframe - Daily Volume - Very Good volume Cmp - 1191 Target - 1836 SL - 976 Here’s a summary of Jubilant Pharmova Ltd’s Q1 FY25 results: Financial Highlights Net Profit: Jubilant Pharmova reported a net profit of INR 482.10 crore, a substantial increase from INR 6.40 crore in the same quarter last year1. Revenue: The total revenue for the quarter was INR 1,731.70 crore, up by 9.12% YoY1. Operating Profit: Operating profit surged to INR 556.70 crore, a remarkable 596.75% increase YoY1. Operational Highlights Operating Margin: The operating margin improved significantly to 32.15%, up by 538.49% YoY1. Expenses: Total operating expenses decreased by 33.13% QoQ to INR 1,175 crore1. Comparative Performance Quarter-over-Quarter: Compared to the previous quarter, revenue grew by 3.2%, and net profit increased by 5.6%1. Outlook The strong performance in Q1 indicates a positive trend for the rest of the fiscal year, driven by robust revenue growth and improved operational efficiency.
NSE:JUBLPHARMALong
by VCharts_TA